NIREUS: Registrational Trial of Ridaforolimus-Eluting Stent (NIRsupreme) for Use in Coronary Artery Disease.
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2016
Price : $35 *
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Coronary artery disease
- Focus Registrational; Therapeutic Use
- Acronyms NIREUS
- 21 Dec 2016 According to a Medinol media release, results from this trial presented at the opening Late Breaking Trial session of the 28th annual Transcatheter Cardiovascular Therapeutics (TCT2016) scientific symposium.
- 17 May 2016 Results (n=302) published in a Medinol media release.
- 17 May 2016 According to a Medinol media release, results of this trial were presented at the EuroPCR 2016 conference.